Prostate-specific Membrane Antigen Targeted Plasmon-enhanced Raman Spectroscopy Reporters for Molecular Imaging of Prostate Cancer

Case ID:
C13637
Disclosure Date:
5/13/2015
Description:
Unmet Need:
Non-invasive assessment of tumor burden and cancer-selective treatment in prostate cancer. This approach is will allow visualization in real-time of the distribution and action of therapeutic agents in vivo by transducing the presence of PSMA at the tissue level to characteristic Raman spectral patterns. This nanoplex platform, therefore, directly enables the real-time imaging of prostate tumor (critical in surgical margin definition) while inhibiting the growth of prostate tumor cells.
Technical Overview:
We have designed and engineered a nanoplex containing surface enhanced Raman spectroscopy (SERS) reporter to target prostate-specific membrane antigen (PSMA), which is expressed on the cell surface of near all prostate cancers. In this design, the PSMA-specific SERS tag, which is encoded with Raman signal molecule (4-nitrothiophenol), can target the PSMA overexpressed prostate tumor cells through the urea-based small molecule inhibitor. The unusually high affinity of the PSMA-targeted SERS probe – higher affinity than any species reported for targeting PSMA – makes it ideal for molecular radiotherapy, which requires a high-affinity interaction for long residence times of the therapeutic with tumor. Moreover, plasmonic heating of the SERS reporter can also be exploited to kill the tumor cells via the photothermal effect. Finally our reporters can be readily linked with therapeutic moieties, including but not limited to therapeutic radionuclides, prodrug enzymes and siRNA, to offer combined imaging and therapy for aggressive prostate tumors.
 
Stage of Development:
We have designed and synthesized an Au nanostar-based SERS reporter. we then conjugated a urea-based PSMA-specific inhibitor with our SERS reporter. We observe that the urea-SERS reporter conjugate exhibits extremely strong affinity toward PSMA+ PC3-PIP cells with an IC50 value of 2.0×10-13 nM, nearly four orders of magnitude lower than the value of the urea-based small molecule inhibitor alone, analogs of which are currently used as clinical imaging agents to detect prostate cancer. Urea-SERS tag conjugates not only inhibit the growth of PC3-PIP cells but also be toxic to them, possibly due to selective internalization of the conjugate
Publication:
Unpublished
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Prostate-specific Membrane Antigen Targeted Plasmon-enhanced Raman Spectroscopy Reporters for Molecular Imaging of Prostate Cancer PCT: Patent Cooperation Treaty United States 15/778,236 5/23/2018     Pending
Inventors:
Category(s):
For Information, Contact:
Jon Gottlieb
jgottl10@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum